Relevance of the international prognostic index in the rituximab era

Journal of Clinical Oncology

Volumn 29, Issue 1, 2011, Pages

  Tay, Kevin ^a   Tai, David ^a   Tao, Miriam ^a   Quek, Richard ^a   Ha, Tam Cam ^a   Lim, Soon Thye ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LETTER; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; HEALTH STATUS INDICATORS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 79951968729     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.7677     Document Type: Letter

References (8)

1. Ziepert M, Hasenclever D, Kuhnt E, et al: Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28:2373-2380, 2010
2. Pfreundschuh M, Trumper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
3. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
4. Glass B, Kloess M, Bentz M, et al: Dose-escalated CHOP plus etoposide (Mega- CHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 107:3058-3064, 2006
5. Anonymous: A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
6. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004 (Pubitemid 38970554)
7. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004 (Pubitemid 38970553)
8. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007